← Leaderboards
Michael Frumovitz
University Of Oklahoma Hlth Sciences Ctr
$1,329,979
Attributed
$3,187,121
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $595.1K · FY2016–23$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,187,121 · 2
By mechanism
R01$1,605,634 · 1
T32$1,581,487 · 1
Top collaborators
- Doris Mangiaracina Benbrook4 shared
- Karen Hsieh Lu3 shared
- Anil K Sood3 shared
Most similar at University Of Oklahoma Hlth Sciences Ctr
Same institution · by research overlap
- Doris Mangiaracina Benbrook$6,963,868
- Kelly J William$238,727
- C V Rao$713,988
- Rajani Rai$376,490
Others in their field
Top investigators on “Cervical Cancer Prevention”
- Philip J Disaia · University Of California Irvine$78,859,922
- Leonard Freedman · Leidos Biomedical Research, Inc.$52,542,130
- Lynn Briscoe · Leidos Biomedical Research, Inc.$25,475,449
- Joel Palefsky · University Of California San Francisco$19,203,187
- Augusto C Ochoa · Louisiana State Univ Hsc New Orleans$17,198,066
- Paula Gonzalez-Maya · Fundacion Inciensa$17,061,460
Research focus
Cervical Cancer PreventionCervical DysplasiaCell TransformationCervicalAftercareBindingAntineoplastic AgentsBiological MarkersBiopsyAdjuvantCancer Cell LineCancer Clinical TrialCancer EtiologyCancer PatientCancer TherapyBioavailableCapsuleCarcinogenesisCell CycleCell Cycle ArrestApoptosisCell Cycle ProgressionCell Cycle ProteinsCervix Neoplasms
Grant awards (7)
Training of Academic Gynecologic Oncologists$561,727
T32 · FY2023 · CA
Training of Academic Gynecologic Oncologists$547,824
T32 · FY2022 · CA
Training of Academic Gynecologic Oncologists$471,936
T32 · FY2021 · CA
Targeting HPV Consequences in a Cervical Cancer Clinical Trial$408,607
R01 · FY2019 · CA
Targeting HPV Consequences in a Cervical Cancer Clinical Trial$176,894
R01 · FY2018 · CA
Targeting HPV Consequences in a Cervical Cancer Clinical Trial$425,061
R01 · FY2017 · CA
Targeting HPV Consequences in a Cervical Cancer Clinical Trial$595,072
R01 · FY2016 · CA